Abbott Laboratories (NYSE: ABT) — Priced Like Medtronic, Built Like Stryker

Date: June 11, 2026 · Price at analysis: ~$89.17 (2026-06-10) · Market cap: ~$155B · EV: ~$182B (post-Exact-Sciences) · CIK: 0000001800 Sector: Health Care — Diversified Medtech (Medical Devices, Diagnostics, Nutrition, Established Pharmaceuticals) · Fiscal year-end: December

This is an independent research article. The analysis below takes no buy/sell recommendation and states no price target; valuation is discussed only as embedded expectations and scenarios. The single, deliberate exception is the clearly-labeled Author’s Take block immediately below.

⚡ Author’s Take

This block is the author’s own subjective opinion. It is not investment advice and is general information only. Everything below this block carries no position and no price target, by design.

Verdict: BUY / accumulate — a genuinely high-quality, scale-advantaged diversified medtech compounder that the market has marked down to the cheapest it has been versus its own history in a decade, on a cluster of fears its own near-term numbers keep refuting. I’d accumulate in the high-$80s/low-$90s and add aggressively into the low-$80s (the 52-week low and the level where you are paid to wait via a Dividend-King payout). Fair-value zone ~$105–$122 — roughly the base case, where a mid-teens-growing device franchise stops being valued like a no-growth one.

Tag: “The crown jewel, on the clearance rack for a robot that hasn’t shown up.”

Abbott is down ~36% from its $139 high to ~$89, sitting near 52-week lows at the 23rd percentile of its own ten-year valuation history — a level it has reached only in genuine crises. The bear file is four items: (1) GLP-1 weight-loss drugs will shrink the FreeStyle Libre / CGM market; (2) the NEC infant-formula litigation is an unquantified multi-billion tail; (3) Diagnostics is structurally impaired by COVID-test runoff and China price cuts; (4) the $23bn Exact Sciences deal diluted EPS and levered the balance sheet. Each is real. But weigh them against what actually happened: Libre/CGM grew +17% to ~$7.6bn in 2025 with zero visible GLP-1 drag and the category <20% penetrated; Abbott won summary judgment in the first three federal NEC bellwether trials (May/Aug/Oct 2025), a far more important signal than the lone $495m Missouri verdict that detonated the stock; and normalized earnings actually grew in 2025 — the apparent “−51% earnings collapse” is a pure accounting artifact of a $7.5bn non-cash tax benefit that inflated the 2024 base. The market is extrapolating a set of near-term/cyclical drags into a permanent ~4–5% growth verdict, which is what the reverse-DCF says is priced. That is not a ~4% business: Medical Devices (48% of revenue, 34% margins) is compounding +11.9% organically.

The central mispricing is captured in one comparison. At ~15.8× forward adjusted EPS, Abbott trades below every pure-play double-digit medtech grower (Stryker ~18.5×, Boston Scientific ~13×, Edwards ~25×, Dexcom ~24×) and below the diversified large-caps (JNJ ~19×, Thermo ~18×) — it is valued like the slow cohort (Medtronic ~12.5×, Becton ~11×) despite a faster-growing, higher-margin mix. You’re paying a Medtronic multiple for a Stryker-quality engine, plus three ballast businesses for free. Two further points seal the conviction: a CFO and a senior director both bought stock with personal cash near the lows (a rare tell for a name whose insiders only ever sell to cover taxes), and the downside is unusually well-protected — the bear scenario lands only ~5% below spot precisely because the multiple is already at a trough, so there is little de-rating room left. Framing: contrarian quality-compounder at a value-medtech price. Conviction: medium-high. Flips more bullish if the NEC MDL resolves favorably (more bellwether wins / a capped settlement) or Diagnostics margins inflect off the China/COVID trough. Flips bearish if Libre organic growth decelerates below ~10% (the GLP-1 bear thesis starting to bite) or a large adverse NEC verdict survives appeal and sets a multi-billion settlement floor.

1. Executive Summary

Abbott Laboratories is a ~$44bn-revenue, 122,000-employee diversified healthcare company — one of the few genuine four-legged stools in the sector. It operates Medical Devices ($21.4bn, 48% of sales — the growth engine, anchored by the FreeStyle Libre continuous glucose monitor and a St.-Jude-derived cardiovascular franchise), Diagnostics ($8.9bn — Core Lab instruments/reagents plus rapid testing), Nutrition ($8.5bn — #1 infant formula Similac and adult Ensure/Glucerna), and Established Pharmaceuticals/EPD ($5.5bn — branded generics sold only in emerging markets). AbbVie was spun off in 2013; St. Jude Medical and Alere were acquired in 2017; Exact Sciences (Cologuard) closed in March 2026.

The business is higher-quality than its current multiple implies. Three of the four legs sit in structurally attractive, high-barrier industries (medtech, IVD diagnostics), and the crown jewel — Libre — is a textbook scale-plus-switching-cost annuity: ~$7.6bn of CGM revenue in 2025, +17%, the third consecutive year it added more than $1bn, in a market management believes is less than 20% penetrated (10–12m users today vs. a 70–80m opportunity). Medical Devices as a whole grew +11.9% organically at a 33.7% operating margin. The two weaker legs — Nutrition (consumer-staples economics, recall-scarred) and EPD (an emerging-market distribution franchise, not a moat) — provide ballast and EM exposure rather than competitive advantage. The clearest competitive weakness is electrophysiology, where Abbott entered the pulsed-field-ablation (PFA) transition years behind Boston Scientific’s Farapulse and holds low-single-digit share; its Volt PFA system (US-approved 2025) is the swing factor on whether it recovers to a credible #3.

Financial quality is high once the accounting noise is removed. GAAP earnings are distorted in both directions by a single item: a $7.5bn non-cash deferred-tax valuation-allowance release in Q4 2024 that inflated 2024 GAAP net income to $13.4bn and makes 2025’s $6.5bn look like a collapse. It is not — normalized 2024 EPS was ~$3.38, so 2025’s $3.72 GAAP / ~$5.15 adjusted grew. Abbott’s adjusted EPS is the clean, honest kind: the add-backs are acquisition-intangible amortization and restructuring; stock-based compensation is left in the cost base, not added back. Free cash flow was ~$7.4bn (covering the dividend ~1.8×), the pre-deal balance sheet was a fortress (~$4bn net debt, 0.35× EBITDA), and returns are solid (~12% ROIC, ~13% normalized ROE). The Exact Sciences deal has since levered the balance sheet to ~$26.8bn net debt (~2.2–2.7× EBITDA), which the buyback (deliberately modest) is subordinated to paying down through 2027.

Capital allocation is disciplined. Abbott is a Dividend King (50+ consecutive years of increases), pays out ~55% of FCF, grew the marquee assets (Libre, structural heart) organically at ~6.6%-of-revenue R&D, and has a credible deleveraging record (4.5×→2.2× after the 2017 deals). The Exact Sciences acquisition ($105/share, ~$23bn EV, ~7.7× sales) is a full price that demands flawless execution, but it is an on-strategy adjacency (doubling the Diagnostics TAM with the dominant colorectal-cancer screen) rather than empire-building, and management’s incentive scorecard is per-share- and return-oriented (the 2025 sales miss correctly zeroed a quarter of the CEO’s bonus).

Valuation is the crux, and it favors the buyer. On adjusted earnings ABT is cheap both cross-sectionally (15.8× vs. an 18–19× peer median for its growth/margin profile) and against its own history (23rd percentile). A sum-of-the-parts brackets ~$82–106/share (midpoint ~$94), and a reverse-DCF shows the market is pricing only ~4–5% perpetual growth versus management’s high-single-digit-revenue / double-digit-EPS algorithm. Scenarios span roughly $85 bear / $108 base / $131 bull, a favorable skew because the de-rating has already happened. This memo carries no recommendation and no price target.

2. Business Overview

Abbott (HQ Abbott Park, Illinois; founded 1888; ~122,000 employees) discovers, manufactures and sells healthcare products across four reportable segments. FY2025 revenue was $44,328M, +5.7% reported (+7.9% organic ex-COVID/FX), up from $41,950M (2024) and $40,109M (2023). The business is overwhelmingly recurring — consumable sensors, reagents, formula, and chronic-care branded drugs — and notably international: 61% of sales are ex-US, with emerging markets ~37% of the total (Germany, China, Switzerland, India and Japan are the largest country markets after the US). That geographic breadth is both a growth asset (EM volume) and a source of the COVID/China/FX noise in the reported numbers.

2.1 The four segments (FY2025)

(Source: FY2025 10-K, Note 16 segment table. “Total company” revenue $44,328M includes ~$17M of Other.)

The headline structural fact: Medical Devices is now nearly half of revenue and 61% of segment operating earnings, and it grows fastest. The “four uncorrelated legs” framing has quietly become “Medical-Devices-plus-three-ballast.” Device operating margin (33.7%) is roughly double Nutrition’s and Diagnostics’. This is the single most important shift for valuation — the part of Abbott that deserves a premium medtech multiple is now the largest part.

2.2 Medical Devices — the engine

The segment comprises Diabetes Care (FreeStyle Libre CGM — ~$7.6bn of CGM revenue in 2025, total Diabetes Care ~$8.0bn, +17%), Cardiovascular (Structural Heart: MitraClip, TriClip, Tendyne, Navitor, Amulet; Electrophysiology: EnSite mapping, the new Volt PFA; Rhythm Management: Aveir leadless pacemakers; Vascular), Heart Failure (CardioMEMS PA-pressure sensor, HeartMate LVAD), and Neuromodulation. The razor/razorblade economics are excellent: Libre readers and apps are low-margin customer-acquisition tools, while the 14-day sensors are a perpetual high-margin consumable annuity; structural-heart and EP procedures lock in physicians trained and proctored on Abbott’s specific systems. Medical Devices grew organic +11.9% in 2025 and +13.7% in 2024, with margins expanding 31.4%→33.7% over three years.

2.3 Diagnostics — a real moat in a cyclical trough

Core Lab (Alinity/ARCHITECT analyzers placed into hospital/reference-lab accounts, pulling years of high-margin assay reagents under multi-year contracts), Molecular, Point of Care (i-STAT), and Rapid Diagnostics (BinaxNOW, Panbio, ID NOW). The installed-base lock-in is genuine — switching analyzers means revalidation, retraining and workflow disruption — but the segment is masked by two drags: COVID-testing revenue collapsed from a ~$8bn peak (2021–22) to $1.6bn (2023) → $747m (2024) → $297m (2025), and China volume-based procurement (VBP) is compressing reagent pricing (China revenue fell $2.25bn→$1.91bn over two years). Segment margin fell 24.4%→19.5%. Ex-COVID, Core Lab grew ~7%. The pending recovery of this margin is a free option embedded in the stock.

2.4 Nutrition — #1 formula, recall-scarred, adult tailwind

Pediatric (Similac infant formula — historically #1 in the US at ~40% share) and Adult (Ensure, Glucerna, the new GLP-1-oriented Protality). Nutrition grew just +0.4% organic in 2025 (US pediatric volume soft after a lost WIC contract; price up, volume down), though margin still ticked to 18.4%. The 2022 Sturgis, Michigan plant shutdown and recall proved the brand is damageable and ceded share to Reckitt/Enfamil; the NEC preterm-formula litigation is a live brand and financial overhang. Adult nutrition is the higher-quality half — a structural beneficiary of aging demographics, the protein trend, and GLP-1-driven muscle-preservation needs.

2.5 Established Pharmaceuticals (EPD) — a distribution franchise

Branded generics sold only outside the US, in emerging markets, across cardiometabolic, GI, CNS/pain and women’s-health categories, plus a growing biosimilars push. EPD grew +7.4% organic in 2025 at a 23.3% margin. Individual branded generics have no durable advantage; what protects EPD is the aggregate of brand trust, multi-country distribution scale, and local registration/regulatory barriers — a steady, cash-generative franchise rather than a moat.

2.6 Revenue quality

Roughly 90%+ of revenue is recurring and consumable-driven. There is meaningful customer-channel concentration in US distribution (wholesalers) and in Diagnostics (large hospital/lab accounts), but no single product is large enough to sink the company — the most concentrated exposure is Libre at ~17% of sales, itself a high-growth asset. The diversification is real: a diabetes device, a hospital diagnostic, a consumer staple and an EM pharma distributor are about as uncorrelated as healthcare sub-sectors get.

3. Industry Dynamics

Abbott straddles four distinct industries with very different structures. The verdict depends on weighting — and the weighting now favors the good industries, because devices and diagnostics are ~68% of revenue and an even larger share of profit.

3.1 Medtech / CGM / cardiovascular — structurally excellent

Medical devices is one of the better structures in healthcare. The relevant sub-markets are consolidated oligopolies with high barriers: multi-year clinical trials, FDA PMA/510(k) pathways, physician relationships and procedural training, and reimbursement coding that takes years to secure. Critically, pricing runs through an agency relationship — the physician chooses the device, the payer pays, and the patient bears the switching risk — which confers durable pricing power and insulates incumbents from the price competition that erodes most manufacturing businesses.

• CGM is a three-firm market (Abbott ~57% global revenue share, Dexcom ~35%, Medtronic ~7% in 2024) growing into a vastly under-penetrated TAM (~$10.5bn in 2025, projected ~$29bn by 2030). In Marathon capital-cycle terms this is the favorable quadrant: demand compounding, supply concentrated among three disciplined players, no flood of new capacity.
• Structural heart (TEER, TAVR, LAA, TMVR) is an Abbott/Edwards/Medtronic/Boston-Scientific contest with genuine innovation races but durable category leadership for first movers.
• Electrophysiology is the exception that proves the rule — a fast technology transition (PFA) where a late entrant (Abbott) can lose a decade of position quickly.

Verdict: structurally attractive and getting more so — EU MDR and rising FDA evidentiary bars raise the cost of entry and favor large incumbents like Abbott.

3.2 In-vitro diagnostics (IVD) — attractive but pressured

A tight global oligopoly (Roche #1, then Abbott, Siemens Healthineers, Danaher/Beckman) with installed-base lock-in and recurring reagent economics. Structurally good, but currently squeezed by three forces: the COVID-testing hangover, China VBP (a government program that auctions reagent volume at steep discounts), and general reimbursement pressure. The core franchise economics are intact; the question is whether 19.5% segment margins are a cyclical trough or a structural reset. Exact Sciences extends Abbott into the higher-growth cancer-diagnostics adjacency (colorectal screening, MRD, MCED), doubling the addressable market from ~$60bn to >$120bn.

3.3 Nutrition — consumer-staples economics

Lower barriers than devices: brand and manufacturing scale matter, but private-label competition, commoditization, and recall/tail risk (infant formula is a product where a manufacturing lapse becomes a national news event and a litigation magnet) cap the structural attractiveness. The adult/aging sub-pool is the more defensible, demographically-levered half. Verdict: structurally mediocre, with one good sub-segment.

3.4 Emerging-market branded generics (EPD) — fragmented but protected

A fragmented industry where individual products commoditize, but multi-country distribution and registration scale protect at-scale incumbents. Verdict: a fine cash-generative business, not a high-return one.

3.5 Overall industry verdict

Net structurally good, and improving in mix. The two segments that matter most to value — Medical Devices and Diagnostics — sit in high-barrier, agency-priced, consolidated industries, and the regulatory trend (EU MDR, higher FDA bars) widens incumbents’ moats. The two weaker legs are the smaller profit pools. A pure-play of Abbott’s device-and-diagnostics core would screen as a clearly attractive industry; the nutrition and EPD ballast dilute that to “good,” which is part of why the blended multiple sits below the device peers.

4. Competitive Position

Applying the Greenwald taxonomy (the three genuine advantages: supply/cost, demand/captivity, and economies-of-scale-plus-captivity), Abbott’s moat is concentrated and real where it counts — and absent in two legs. The test that matters: if the advantage disappeared, would a financial outcome (ROIC, share stability, pricing) deteriorate? For Libre, Core Lab and structural heart, yes. For Nutrition and EPD, only modestly.

4.1 FreeStyle Libre — the crown jewel (scale + captivity + cost leadership)

Libre is the best-selling medical device in history by dollar sales (~$7.6bn of CGM revenue in 2025). The moat is the strongest of the three Greenwald types: economies of scale combined with customer captivity, reinforced by cost leadership. As the highest-volume CGM maker, Abbott has the lowest cost per sensor, which lets it win reimbursement and capture the mass market — basal-insulin Type-2s, non-insulin diabetics, and price-sensitive international/reimbursement geographies — exactly where the TAM is expanding. Once a patient is on Libre, switching is sticky (habit, app/data history, prescriber inertia, payer formularies). Management is explicit that cost leadership is the strategic linchpin as the market expands down-market.

The competitive structure is two regional scale-leaders, not one global monopolist — the most important nuance. Globally Abbott leads (~57% revenue share), but in the US Dexcom holds ~74%, entrenched with intensive-insulin users and endocrinologists on a premium-accuracy product. Abbott dominates internationally and the mass/basal/non-insulin segment. This is Greenwald’s point that scale is share of the relevant (often local or sub-segment) market: both companies have a real moat in their respective strongholds. Verdict: durable, high-return advantage — the single best asset Abbott owns.

4.2 The GLP-1 debate — the fear behind the de-rating

The bear thesis: GLP-1 weight-loss drugs reduce obesity → fewer future Type-2 diabetics → a smaller CGM core. The bull thesis (and Abbott’s): GLP-1s pull more people into the metabolic-care funnel, many of whom land on a CGM, and Abbott monetizes the same wave three ways — Libre, Protality (a GLP-1 muscle-preservation nutrition shake) and Lingo (a consumer biowearable for the non-diabetic wellness market). The near-term evidence sides decisively with the bull case: CGM grew +17% in 2025 with no visible GLP-1 drag, and penetration is the dominant variable (10–12m users of a 70–80m opportunity, <20% penetrated). The genuine, unfalsified question is the 5–10-year diabetes-incidence effect — but the de-rating prices a structural fear that the current numbers contradict. This is the central variant perception.

4.3 Structural heart & heart failure — IP + physician captivity (strong)

Abbott created and leads the transcatheter edge-to-edge repair (TEER) category: MitraClip (mitral) and TriClip (tricuspid TEER, FDA-approved 2024, with CMS national coverage), plus Amulet (LAA occlusion), Navitor (TAVR), and Tendyne (TMVR, FDA-approved 2025). The moat is IP plus physician procedural switching costs — implanters are trained, proctored and outcome-tracked on the specific clip/valve system, creating real captivity. Edwards Lifesciences competes hard with a replacement philosophy (Evoque, PASCAL) against Abbott’s repair approach; the tricuspid contest is genuinely two-sided, but Abbott is a clear co-leader. Heart Failure (CardioMEMS, HeartMate) is a durable high-share niche. Verdict: strong, durable advantage.

4.4 Electrophysiology — the clear lag

EP is Abbott’s most important competitive weakness. Pulsed-field ablation (PFA) is the disruptive shift in atrial-fibrillation treatment, and Abbott entered it years behind. Boston Scientific’s Farapulse dominates (physician surveys put 2025 PFA share at roughly BSX ~58–70%, Medtronic/Affera ~28%, J&J/Varipulse ~11%, Abbott ~3%). Abbott now has the Volt PFA system (FDA-approved and CE-marked 2025) and TactiFlex Duo (RF+PFA); early launches drove US EP +14% and Europe mid-teens in Q1-2026. But here physician switching costs cut against Abbott — implanters have already retooled around Farapulse. Verdict: a real lag; base case is Abbott recovering to a credible #3 on the strength of its EnSite mapping installed base, not regaining leadership. Volt’s 2026 US launch curve is the swing factor.

4.5 Diagnostics Core Lab — installed-base switching costs (strong, cyclically masked)

The Alinity/ARCHITECT razor/razorblade model is a genuine switching-cost-plus-scale moat: place an analyzer, win years of recurring reagent pulls. The advantage is intact and simply buried under COVID/China cyclicality. Roche, Siemens and Danaher are formidable, but the oligopoly is stable. Verdict: durable moat in a cyclical trough — the margin recovery is a free option.

4.6 Nutrition & EPD — moderate-to-weak

Nutrition: brand (Similac, Ensure) plus manufacturing scale give a moderate, eroding moat — the Sturgis recall proved the brand is damageable, private label pressures pediatric, and infant formula carries litigation tail risk. EPD: a distribution franchise, not a moat — protected by EM distribution/registration scale in aggregate, but with no product-level advantage. These are the weakest legs on competitive-advantage grounds; they are ballast and EM exposure, not durable value creators.

4.7 Diversification — resilience asset and conglomerate discount, simultaneously

Abbott’s four-segment structure is a genuine quality attribute: no single product collapse — a recall, a patent loss, a reimbursement cut, an adverse verdict — can sink the company, and the legs are reasonably uncorrelated. That resilience is real and under-weighted by single-product CGM bears. But the market applies a mild conglomerate discount: a sum-of-the-parts would value Libre and Devices at rich medtech multiples and EPD/Nutrition at staples/EM multiples, and the blended ABT multiple sits below what the parts justify. The diversification is both a buffer and the source of the discount — and a catalyst-rich situation if management ever chose to surface the value (a Nutrition or EPD separation is not on the table today, but the optionality exists).

4.8 Competitive verdict

Overall: a durable, high-return advantage concentrated in the two-thirds of the business that matters most (devices + diagnostics), one clear competitive hole (EP), and two ballast legs. The moat shows up in the financial outcomes Greenwald demands — sustained high ROIC in devices, stable multi-year CGM and IVD leadership, and pricing power through agency relationships.

4.9 The capital-cycle (Marathon) read

The supply-side lens reinforces the same conclusion. In CGM, demand is compounding into a vastly under-penetrated TAM while supply is concentrated among three disciplined incumbents — no flood of new capacity, no irrational pricing, the favorable quadrant of the capital cycle. The barriers (clinical evidence, reimbursement, manufacturing scale, app ecosystems) deter the new entrants that high returns normally attract; Dexcom’s Stelo and Abbott’s Lingo expanded the category (into wellness) rather than triggering a price war. In structural heart, the capital cycle is early-innings — Abbott and Edwards are still building the TEER/TMVR markets, so returns are protected by category growth rather than threatened by overcapacity. The one place the cycle works against Abbott is PFA, where a genuinely disruptive technology drew rapid capital and a fast-mover (Boston Scientific) captured the high-return position before Abbott arrived — a reminder that even a strong incumbent can be on the wrong side of a capital cycle in a single sub-market. In Diagnostics, China VBP is a regulator deliberately compressing the cycle (auctioning volume to crush price), which is exactly why the segment margin fell — but the installed-base lock-in means the franchise survives the squeeze. Net: Abbott sits in the favorable quadrant of the capital cycle in its two largest, highest-return franchises, with one self-inflicted exception (EP) and one regulator-driven one (China IVD).

5. Growth History and Forward Opportunities

5.1 The history — distorted by COVID, real underneath

Abbott’s reported growth is noisy because of the COVID-testing boom/bust: revenue spiked to $43.1bn (2021) and $43.7bn (2022) on a ~$8bn COVID-testing windfall, then looked flat-to-down as that washed out ($40.1bn in 2023) before re-accelerating to $44.3bn (2025). The honest read is the ex-COVID base business, which has compounded high-single-digits throughout: +7.9% organic ex-COVID in 2025, led by Medical Devices +11.9% and EPD +7.4%, with Diagnostics (−4.3%) and Nutrition (+0.4%) the drags. Over a longer arc, the post-2017 reshaping (St. Jude/Alere in, AbbVie already out) turned Abbott into a device-led grower, and the organic-innovation record is strong — Libre and the structural-heart suite were built, not bought.

5.2 The growth algorithm

Management’s stated medium-term algorithm is high-single-digit organic revenue growth, double-digit adjusted EPS growth, and 50–70bps/year of operating-margin expansion. The 2025 result delivered it (organic ~7.9% ex-COVID, adjusted EPS +~10% to $5.15), and 2026 guidance was 6.5–7.5% organic with adjusted EPS originally $5.55–$5.80 (revised to ~$5.48 midpoint to absorb $0.20 of Exact Sciences dilution). The reverse-DCF shows this algorithm is largely not priced at $89.

5.3 Forward drivers — quality, diversified, mostly de-risked

• Libre / Diabetes Care (the largest driver): continued penetration of a <20%-penetrated TAM; Libre 3 Plus and Libre 5; a dual glucose-ketone sensor (FDA-filed, opens ~5m SGLT2 users + insulin-pump integration); a lactate sensor; a Type-2 non-insulin indication; Lingo in the OTC/wellness market. Management targets continued mid-teens CGM growth.
• Structural heart & EP: TriClip and Tendyne ramps (with CMS coverage), Navitor TAVR expansion, the LAA pivotal trial, and the Volt PFA US launch (the share-recovery option).
• Diagnostics: Core Lab margin recovery off the COVID/China trough, plus the Exact Sciences growth engine (Cologuard’s ~$3bn franchise growing high-teens; Cancerguard MCED optionality).
• Adult Nutrition: aging/protein/GLP-1 tailwinds (Protality, high-protein Ensure, Glucerna).
• EPD: EM volume plus a biosimilars push (oncology, immunology, GLP-1 biosimilars).

5.4 The Libre razor-blade math and the GLP-1 stress test

Because Libre is ~17% of revenue and the single largest swing factor in the bull thesis, it deserves the arithmetic. Libre/CGM revenue ran roughly $5.3bn (2023) → $6.4bn (2024) → $7.6bn (2025) — adding more than $1bn for the third straight year, a ~17% growth rate on a base that is now larger than most standalone medtech companies. The economics are a recurring-consumable annuity: a user wears a sensor replaced roughly every 14 days, so each new user converts into a perpetual, high-margin reorder stream; the reader/app is a near-zero-margin acquisition cost. With management’s framing of ~10–12m users today versus a 70–80m global opportunity, the installed base — not price — is the growth engine, and an installed-base annuity is the most predictable revenue form there is.

Stress-testing the GLP-1 bear case against this math: even on a pessimistic assumption that GLP-1 adoption eventually flattens new-diabetic incidence, (a) the existing diabetic pool is decades from saturation at <20% CGM penetration; (b) GLP-1 and basal/oral/Type-2 patients are themselves CGM candidates (Abbott’s RCT data show HbA1c benefit in basal-insulin Type-2s); and © Lingo opens an entirely non-diabetic wellness TAM. For the bear case to bite the numbers (not just sentiment), Libre growth has to decelerate below ~10% — which is the explicit falsification test. It has not; 2025 was +17%. The de-rating is pricing a fear that the franchise’s own cash register contradicts.

5.5 Growth verdict

High-quality growth. It is organic-led (the marquee assets were internally developed), broad-based across uncorrelated drivers, margin-accretive (mix shift toward 34%-margin devices), and sits in under-penetrated, agency-priced markets. The two qualifiers are the EP lag (a drag, not a hole in the algorithm) and the GLP-1 long-tail question on the largest driver. Verdict: durable, diversified, high-quality growth that the current valuation does not credit.

6. Financial Quality

6.1 The one item that distorts everything: the 2024 tax gain

The single most important quality-of-earnings fact: GAAP net income is distorted in both directions by a $7.5bn non-cash deferred-tax valuation-allowance release booked in Q4 2024. Abbott restructured certain foreign affiliates, concluded that previously-reserved foreign deferred tax assets were now realizable, and released the valuation allowance — producing a −91.1% effective tax rate in 2024 (10-K Note 15) and inflating 2024 GAAP NI to $13,402M against operating income of only $6,825M.

The implication is decisive: the apparent “−51% earnings collapse” in 2025 is an accounting artifact. Normalized, 2025 earnings grew over normalized 2024. Any screen showing ABT’s GAAP earnings down ~51% (or its TTM P/E at ~24×) is reading the inflated 2024 base. The honest scoreboards are adjusted EPS and free cash flow.

6.2 Adjusted EPS — the clean kind

Adjusted diluted EPS: FY23 $4.44 → FY24 $4.67 → FY25 $5.15 (the proxy confirms $5.15 hit the maximum bonus threshold), with FY26 guidance $5.55–$5.80, revised to ~$5.48 midpoint for the Exact Sciences dilution. The GAAP→adjusted bridge is dominated by acquisition-intangible amortization ($1,682m in 2025, from St. Jude/Alere/CSI) plus restructuring and discrete deal/tax items. Crucially, stock-based compensation (~$664m) is left in the adjusted cost base — it is not added back. This is the legitimate-amortization kind of adjustment, not the aggressive kind. Adjusted EPS is a fair representation of cash-generative earnings power, and it is corroborated by FCF (below).

6.3 Margins

GAAP gross margin was ~56.8% in 2025; adjusted gross margin ~57% (recovering toward the pre-pandemic ~59–60% but not yet there), with management targeting 50–70bps/year of operating-margin expansion. The margin story is a favorable mix shift: Medical Devices (33.7% segment margin) growing fastest pulls the blend up, while Diagnostics (19.5%, COVID/China-depressed) and Nutrition (18.4%) are the laggards whose recovery/mix-decline is the swing.

6.4 Cash flow and FCF quality

FCF grew from $5.1bn to $7.4bn over three years; FY25 FCF conversion was ~83% of adjusted NI (~$8.9bn) and ~113% of GAAP NI. Importantly, the 2024 tax gain was non-cash — it was reversed straight out of operating cash flow (a −$8.0bn add-back), so OCF was not flattered; cash earnings track adjusted, not GAAP. The dividend is covered ~1.8× by FCF — comfortable, with room to keep growing.

6.5 Balance sheet — fortress, then deliberately levered

This is the figure most data feeds get wrong. At FY2025 year-end (pre-deal), the balance sheet was a fortress: total debt $12.9bn, cash + ST investments $8.9bn → net debt ~$4.0bn, ~0.35× EBITDA, current ratio 1.58×, with positive tangible book (~$22.6bn). The Exact Sciences close (March 2026) transformed it: the Q1-2026 10-Q shows total debt $34.0bn (long-term $29.6bn + current $4.4bn, after a $20bn senior-notes issuance) and goodwill up to $35.2bn (from $24.0bn). Net of $7.3bn liquidity, current net debt is ~$26.8bn, ~2.2× pro-forma EBITDA (management cited ~2.7× gross at close) — a comfortable, investment-grade level that the dividend and deleveraging are prioritized over buybacks to bring back toward ~2× through 2027. (This is why yfinance shows EV ~$182bn — it reads the post-deal balance sheet; the discrepancy with the pre-deal 10-K figure is timing, not error.) Goodwill + intangibles now modestly exceed tangible equity, the normal consequence of a large cash acquisition; this is a cash-flow-coverage story, not a balance-sheet-risk story.

6.6 Returns

Stripping the 2024 tax gain: normalized ROE ~13% (2024 and 2025), ROA ~7.8%, and ROIC ~12% (NOPAT ~$6.8bn / invested capital ~$56bn pre-deal). ROIC is dragged by ~$24bn of legacy St. Jude/Alere goodwill — Medical Devices ROIC sits well above the corporate average, while Diagnostics and Nutrition are dilutive. Post-Exact, near-term ROIC dips (management guided high-single-digit deal ROIC only by year 6), but the operating return profile is strong. Financial-quality verdict: do economics improve with scale? Yes — margins and ROIC rise with the device mix; the only blemishes are the goodwill drag on consolidated ROIC and the temporary leverage step-up.

6.7 Five-year financial summary

FY2024 GAAP NI inflated by the $7.5B non-cash tax-valuation-allowance release; normalized ~$5,891M.

The shape tells the story: the 2021–22 COVID-testing bulge (revenue >$43bn, adjusted EPS ~$5.2–5.3), the 2023 air-pocket as COVID washed out (revenue −8%, adjusted EPS to $4.44), and the clean re-acceleration since (adjusted EPS $4.44 → $4.67 → $5.15, with the base business compounding underneath the COVID noise the whole time). Read across the adjusted EPS and FCF rows — not the GAAP-NI row — and Abbott is a steady high-single-digit-to-double-digit compounder that the market is treating as if 2023’s air-pocket were the run-rate.

6.8 Q1-2026 read

Q1-2026: net sales $11,164m (+7.8% reported, +3.7% organic — soft, hit by a weak respiratory/flu season in Diagnostics), adjusted EPS $1.15 (+6%), adjusted gross margin 56.3%. GAAP net earnings fell to $1,077m (from $1,325m) on Exact deal/financing costs and higher interest — the source of the “−19.7% YoY earnings” figure in data feeds, which is deal drag, not operational deterioration (adjusted EPS still grew). Q2-26 adjusted-EPS guide $1.25–$1.31; FY26 organic 6.5–7.5%.

7. Capital Allocation

Verdict up front: disciplined and shareholder-aligned, with one full-priced but on-strategy large deal.

7.1 The dividend — a Dividend King

Abbott has increased its dividend for 50+ consecutive years (a Dividend King), with the 2025 payout $2.40/share (+7.1%), ~$4.1bn paid, ~55% of FCF — comfortably covered with room to grow. Management calls the growing dividend “core to our identity.” For a stock yielding ~2.8% with a covered, growing payout, the income alone pays you to wait through the de-rating.

7.2 Buybacks — deliberately modest, and subordinated

Repurchases are small and explicitly the residual lever: ~$0.6–1.3bn/year (2025 clean open-market repurchases ~$604m). A new $7bn authorization (Oct 2024) remains largely unused because capital is routed first to the dividend, then to M&A, then to deleveraging. This caps buyback as a near-term EPS support through 2027 — a modest negative for per-share growth, but the right priority order given the post-deal leverage.

7.3 R&D and the organic engine

R&D runs ~6.6% of revenue (~$2.94bn in 2025), and the marquee growth assets — Libre and the structural-heart suite — were built, not bought. This is the Marathon “internal compounding” signature: high returns reinvested into proprietary product cycles. It is the strongest evidence that Abbott creates value organically rather than relying on serial dealmaking.

7.4 M&A — a credible record, and a full-priced new deal

The reference deals are St. Jude (~$25bn) and Alere (~$5.3bn) in 2017; leverage peaked ~4.5× and Abbott cut it to ~2.2× in roughly three years — a genuinely strong deleveraging track record, and St. Jude became the spine of the organically-extended structural-heart franchise. Exact Sciences ($105/share, ~$21bn equity / ~$23bn EV, closed March 2026) is a full price — ~7.7× sales — that demands flawless execution and rests on a thin explicit-synergy case (~$100m by 2028); the return comes from sustaining Exact’s mid-teens growth and 70%+ gross margins, not from cost-out. Through a Greenwald/Marathon lens it sits at the disciplined edge: an adjacent extension (doubling the Diagnostics TAM with the dominant colorectal-cancer screen, Cologuard) rather than empire-building, buying the profitable category leader rather than a cash-burning science project. It is dilutive in 2026 (−$0.20) and 2027 (−$0.16), accretive thereafter. Net: a reasonable, on-strategy bolt-on at a price with no margin of safety — the one capital-allocation decision to watch.

7.5 Incentive alignment

CEO Robert Ford (Chairman & CEO since 2021; 2025 total comp $24.2m) is paid on a per-share- and return-oriented scorecard: the annual bonus weights Adjusted Sales (25%), Adjusted EPS (25%), Adjusted ROA (10%), FCF (10%), Structural Heart growth (10%), and product-launch/human-capital goals; the LTI keys on relative TSR vs. peers plus a 3-year contribution metric, with ROE gating the performance-share vesting. The formula bites: the 2025 sales miss correctly zeroed 25% of the bonus (Ford earned 75% of target) even as EPS hit maximum. Say-on-pay has averaged ~91% over six years (solid, if not unanimous). Insider ownership is modest but real, and two insiders bought stock with personal cash near the lows in 2026. Verdict: management has allocated capital intelligently — dividend discipline, organic-innovation bias, credible deleveraging, and an aligned comp structure; the Exact price is the single item reasonable people can debate.

8. Changes and Headwinds — Last Two Years

8.1 The de-rating bridge (why ~36% off the high)

ABT fell from ~$139 to ~$89 — a ~36% de-rating to the 23rd percentile of its own valuation history — on a cluster of overlapping fears. Ranked by importance:

1. NEC litigation + the July 2024 $495m verdict shock — the proximate detonator and the dominant unquantified tail.
2. GLP-1 fears on the Libre/CGM TAM — a sentiment overhang on the crown jewel, contradicted by +17% CGM growth.
3. Diagnostics drag — COVID-test runoff and China VBP compressing growth and margins.
4. Tariffs — management quantified a “few hundred million dollars” 2025 impact (carrying into 2026) but reaffirmed rather than cut guidance (Ford noted that absent tariffs they had been considering raising EPS guidance).
5. Exact Sciences dilution + re-leverage — the −$0.20/−$0.16 EPS drag and the step-up to ~2.7× added a near-term overhang.

The offsets the market appears to under-weight: the three bellwether wins, reaffirmed guidance, two insider buys, a covered and growing dividend, and normalized earnings that actually grew.

8.2 The NEC infant-formula litigation — the swing factor

As of January 31, 2026, Abbott was a defendant in 1,760 pending lawsuits alleging that preterm infants developed necrotizing enterocolitis (NEC) from cow’s-milk-based preterm formula (Similac), on a failure-to-warn theory seeking compensatory and punitive damages; federal cases are consolidated in an MDL in the Northern District of Illinois (since April 2022), with a parallel Canadian class action. The scoreboard is more two-sided than the bear narrative:

• Plaintiff win: a July 2024 Missouri jury awarded $495m (on appeal) — the verdict that detonated the stock.
• Defense wins: the N.D. Ill. court granted summary judgment FOR Abbott in the first three MDL bellwether cases (May, August, October 2025), and an October 2024 Missouri trial returned a defense verdict (later granted a retrial, on appeal).

Three consecutive federal summary judgments are a materially more important data point than one state-court verdict — they suggest much of the MDL inventory may be defensible on causation. Abbott has booked no quantified NEC reserve (ASC 450 boilerplate: “not feasible to predict”), so the market is pricing a distribution, not a point estimate; published analyst tail estimates have ranged from low-single-digit billions to far larger. Related matters: a DOJ criminal investigation (Sturgis manufacturing), an FTC inquiry (WIC bidding), a DOJ-intervened qui tam (Nov 2025) with state-AG complaints (Dec 2025), and shareholder-derivative suits that received preliminary settlement approval (April 2026). This is the single biggest swing factor in the equity — and the asymmetry (bellwether wins vs. no reserve) is precisely what a contrarian wants.

8.3 Strategic / corporate changes

• Exact Sciences acquisition signed Nov 19, 2025; $20bn senior notes priced Feb 2026; deal closed March 23, 2026 — the defining corporate event, doubling the Diagnostics TAM.
• Board: Nita Ahuja, M.D. added (Dec 2025; board to 13). Exec changes: new General Counsel (Cushman, 2025), new EVP Diabetes Care (Scoggins, 2025).
• Buyback: $7bn authorization (Oct 2024).

8.4 Insider activity — a rare conviction tell

On the drawdown, director Daniel Starks (former St. Jude CEO) bought 10,000 shares at ~$92.65 and CFO Philip Boudreau bought 2,200 shares at ~$91.50 (both ~April 28, 2026, code-P open-market purchases). For a company whose insiders almost exclusively receive grants and sell to cover taxes, a sitting CFO and a senior director deploying personal cash near the lows is a modest but genuine signal.

8.5 FDA / regulatory positives

Volt PFA US approval and TactiFlex Duo (the EP share-recovery option); Tendyne TMVR approval (2025); a new Navitor TAVR indication; CMS national coverage for TriClip and CardioMEMS; an FDA filing for the dual glucose-ketone sensor; completed LAA pivotal enrollment. These organic catalysts argue the de-rating overshot the fundamentals. Changes verdict: net thesis-neutral-to-positive — the litigation and GLP-1 overhangs are real but partly de-risking, while the pipeline and deal strengthen the medium-term growth profile.

9. Risk Analysis (Risk Matrix)

The two that matter are #1 (NEC — the binary tail, partly de-risking) and #2 (GLP-1 — the structural growth question, contradicted near-term). #3 (EP) and #4 (Diagnostics) are real but bounded drags. The diversification (#12) makes a catastrophic loss implausible — this is a quality business with a litigation/growth overhang, not a fragile one.

10. Valuation Discussion (Embedded Expectations)

No price target, no recommendation. This section quantifies what the ~$89.17 price implies and brackets scenario outcomes.

10.1 Multiples and peer comparison

At $89.17, ABT trades at ~15.8× forward adjusted EPS, ~15× EV/EBITDA (post-deal), ~3.6× EV/sales, ~4.7% FCF yield, ~2.8% dividend yield — and at the 23rd percentile of its own ten-year valuation history (composite). The cross-sectional comparison is the heart of the thesis:

The crux: Abbott’s Medical Devices segment — 34% margins, +11.9% organic, with Libre +17% — is, on its own, a best-in-class double-digit medtech franchise that the standalone comps (SYK, BSX, EW) value at 18–25×. Yet ABT’s blended multiple (15.8×) sits with the slow, lower-margin cohort (MDT 12.5×, BDX 11.0×) and below the diversified large-caps (JNJ 18.8×, TMO 17.7×). A diversified conglomerate should trade at a modest discount to its fastest pure-play parts — but the ~3-turn gap to SYK/JNJ overstates the dilution given ABT’s superior margin structure and ~7–8% consolidated organic growth (faster than MDT or BDX). You are paying a Medtronic multiple for a Stryker-quality engine.

10.2 Sum-of-the-parts

Valuing each segment off FY25 operating income (grossed to an EBITDA proxy) at sector-appropriate multiples, then netting out ~$2.7bn of unallocated corporate EBITDA drag and post-deal net debt:

Net EV of $146–188bn less ~$27bn post-deal net debt implies equity of ~$119–161bn, or ~$68–92/share pre-Exact-EBITDA contribution — and adding Exact’s ~$3bn revenue franchise at a growth-diagnostics multiple lifts the range to roughly ~$82–106/share, midpoint ~$94. The current EV sits in the lower third of this range. The conglomerate discount is modest (~5–8% at the midpoint), not gaping — the parts are cheap-ish, not screamingly mispriced on a static basis. The load-bearing variable is the Medical Devices multiple: every turn of EV/EBITDA there is ~$5/share. The upside is in the re-rating/recovery, not a hidden-asset gap.

10.3 Embedded-expectations / reverse-DCF

Solving for the growth the price demands (FCF ~$7.4bn base):

• Single-stage Gordon (target EV ~$182bn post-deal): at a 7.5% WACC, the price implies perpetual FCF growth of only ~2.5–3%.
• Two-stage (10yr at g₁, then 2.5% terminal, 7.5% WACC): the price is matched at g₁ ≈ 4–5% for the decade.

Either way, the market is underwriting mid-single-digit growth at best — well below management’s high-single-digit-revenue / double-digit-EPS algorithm. A two-stage at the algorithm’s ~9–10% near-term EPS growth supports an EV ~$235bn+ (~$130/share-equivalent). What the market is pricing correctly: near-term Diagnostics impairment, 2026 deal dilution, genuine GLP-1/NEC tail risks deserving some haircut, and constrained buybacks. What it is pricing incorrectly: extrapolating those cyclical/near-term drags into a permanent ~4% growth animal, when Libre (+17%) and Medical Devices (+11.9% organic) plainly are not that, and normalized earnings grew in 2025. The market is pricing the GLP-1/litigation-impaired path, not the management algorithm — and Abbott’s execution record favors the algorithm.

10.4 Scenario analysis (FY28E adjusted EPS × exit multiple)

The asymmetry is favorable. The bear case lands only ~5% below spot because the multiple is already near its own-history trough — there is limited de-rating room left, so downside is protected by the cheap starting multiple plus a covered ~2.8% dividend. The base case is simply “management does roughly what it says and the multiple drifts back toward a medtech-blend level.” A 2–3-year fair-value zone spans ~$85 / ~$108 / ~$131 with a clear upward skew.

10.5 Which multiple to trust

Most informative: forward adjusted P/E (15.8× — strips the tax/one-time noise, reveals the cross-sectional discount), EV/EBITDA (capital-structure-neutral, right for the SOTP and the leverage step-up), FCF yield (4.7%, anchors the reverse-DCF), and the own-history percentile (23rd — the timing signal). Least informative: GAAP trailing P/E (~24×, distorted by the 2024 tax gain — makes ABT look expensive when it is cheap; discard it) and P/S (~3.6×, a mix artifact blending 34%-margin devices with 18%-margin nutrition — meaningless across that dispersion, which is exactly why the SOTP exists).

10.6 Triangulation

Three independent methods converge on the same conclusion — ABT is cheap-to-fair with an upward skew, not richly valued:

• Cross-sectional multiples say ABT trades ~3 turns below where its growth/margin profile maps on the medtech curve (15.8× vs. an 18–19× peer median).
• SOTP brackets ~$82–106 (midpoint ~$94), with the current EV in the lower third of the range — the parts are worth modestly more than the whole.
• Reverse-DCF says the price embeds only ~4–5% growth versus a high-single-digit-revenue / double-digit-EPS algorithm, i.e. the algorithm is largely unpriced.

The bridge from ~$89 toward the base-case ~$108 requires only two things that are already happening or de-risking: the multiple drifting from the 23rd percentile toward a mid-teens-to-17× medtech blend, and adjusted EPS compounding at roughly the algorithm rate as Exact turns accretive (2027) and Diagnostics anniversaries its trough. Neither requires heroics. The bull-case ~$131 needs an actual earnings re-acceleration plus a fuller re-rate — possible but not the base. Crucially, the downside math is benign: with the multiple already near a decade-low and a covered ~2.8% dividend, the bear case sits only ~5% below spot. The asymmetry — limited downside because the de-rating is largely done, meaningful upside if execution merely holds — is the quantitative core of the thesis.

11. Variant Perception

11.1 Consensus

The market views ABT as a quality but ex-growth diversified healthcare name facing a stack of overhangs — GLP-1 risk to its biggest franchise, an unquantified litigation tail, a structurally pressured Diagnostics business, and a full-priced deal that levered the balance sheet — and prices it accordingly, at a value-medtech multiple (15.8× forward, 23rd-percentile own history). The Wall Street target (~$118) implies the sell-side sees upside, but the multiple the market is paying says it does not believe the growth algorithm.

11.2 The strongest bull case

A high-quality, scale-advantaged medtech compounder is mispriced for fears its own numbers refute. Libre (+17%, <20% penetrated) is not a GLP-1 victim; the NEC litigation is de-risking (three federal bellwether wins) while priced as a multi-billion certainty; Diagnostics margin is a cyclical trough with a free recovery option plus the Exact growth engine; normalized earnings grew in 2025; the dividend is a covered, growing 2.8%; and insiders are buying. At 15.8× for a double-digit-EPS algorithm, with the bear case only ~5% below spot, the risk/reward is skewed up.

11.3 The strongest bear case

The GLP-1 effect is real but slow, and over 5–10 years it caps Libre’s terminal TAM just as the stock’s whole premium rests on Libre; the NEC tail is genuinely unquantified and unreserved, and one large verdict surviving appeal sets a multi-billion settlement floor; Diagnostics’ China/COVID drag is structural, not cyclical; EP is a permanent #3–4; and the Exact deal was an expensive, low-synergy reach that levered the balance sheet right before a litigation storm. In that world ABT is a ~4–5% grower and 15.8× is fair, not cheap.

11.4 The 3–5 assumptions that matter most, and what would falsify each

1. Libre organic growth stays double-digit (GLP-1 is TAM-expansive, not erosive). Falsified by: Libre/CGM organic growth decelerating below ~10% for two+ quarters.
2. NEC resolves at a manageable cost. Bull falsified by: a large verdict surviving appeal or a multi-billion global settlement; bear falsified by: continued bellwether wins / a capped settlement.
3. Diagnostics margin is cyclical, not structural. Falsified by: segment margin failing to inflect off ~19.5% as COVID/China anniversary.
4. The algorithm (HSD revenue / double-digit EPS) holds. Falsified by: a guidance cut to mid-single-digit EPS growth.
5. Exact Sciences sustains mid-teens growth (justifying 7.7× sales). Falsified by: Cologuard growth decelerating as blood-based CRC screening scales.

The variant in one line: the market prices ABT as a permanently low-growth, litigation-impaired conglomerate; the evidence says it is a still-compounding, scale-advantaged medtech franchise whose two scariest fears (GLP-1, NEC) are contradicted or de-risking in the near-term data — and the multiple has already de-rated to a level that makes the disagreement asymmetric in the buyer’s favor.

12. Fact vs. Interpretation

13. Open Questions

1. NEC aggregate exposure. With no reserve booked and 1,760 suits, what is the realistic settlement range, and do the federal bellwether wins hold on appeal? This is the dominant unknown.
2. GLP-1’s long-tail diabetes-incidence effect. Does 5–10-year obesity reduction eventually cap Libre’s terminal TAM, or does metabolic-monitoring (Lingo/OTC) more than offset? Unfalsifiable today.
3. Volt PFA trajectory. Can Abbott recover to a credible #3 in PFA off the EnSite installed base, or is EP a permanent also-ran?
4. Diagnostics margin floor. Is ~19.5% a cyclical trough (COVID/China anniversary) or a structural reset?
5. Exact Sciences durability. Does Cologuard sustain mid-teens growth against blood-based CRC screening, justifying 7.7× sales — and is Cancerguard/MCED reimbursement achievable?
6. Tariff escalation. Does the trade-policy hit stay at “a few hundred million,” or escalate?
7. Pace of deleveraging vs. buyback resumption — when does the $7bn authorization actually get used?

14. What Must Be True

Bull case — what must be true

• Libre stays a double-digit grower (GLP-1 expands, not shrinks, the metabolic-monitoring funnel) and CGM penetration keeps climbing from its low base.
• NEC resolves at a manageable cost — bellwether wins hold, settlements are capped well below the scary tail.
• Diagnostics margin inflects off the COVID/China trough, and Exact’s growth engine layers on.
• The multiple normalizes toward a mid-teens-to-17× medtech-blend level as the algorithm proves out.
• Falsification test: Libre/CGM organic growth decelerates below ~10% for two+ quarters, or a large NEC verdict survives appeal and anchors a multi-billion settlement. Either breaks the bull thesis.

Bear case — what must be true

• GLP-1 structurally caps Libre’s terminal TAM, hollowing out the premium the whole stock rests on.
• NEC becomes a multi-billion, unreserved liability that survives appeal.
• Diagnostics’ China/COVID drag is structural, EP is permanently lost, and the algorithm slips to mid-single-digit EPS growth — making 15.8× fair, not cheap.
• Falsification test: continued bellwether wins / a capped NEC settlement, or Diagnostics margin inflecting and Libre holding mid-teens growth. Either breaks the bear thesis.

The single most important variable is the joint resolution of (a) Libre’s growth durability and (b) the NEC litigation — the two together determine whether ABT is a still-compounding quality medtech at a value price (bull) or a fairly-priced, litigation-impaired ex-grower (bear). The near-term data leans bull; the tail risks keep it from being a layup.

15. Source Appendix

Primary sources: Abbott FY2025 10-K (filed 2026-02-20), FY2024 10-K (2025-02-21), Q1-2026 10-Q (2026-04-29), 2026 DEF 14A proxy (2026-03-13), and 8-Ks (Exact Sciences merger 2025-11-19, $20bn notes 2026-02-26, deal close 2026-03-23, derivative settlement 2026-04-17); SEC EDGAR XBRL company facts; SEC Form 4 insider filings; Abbott earnings-call transcripts (Q1-2026 through Q4-2023) and the Exact Sciences M&A call (2025-11-20); AZI fundamentals/valuation-index/news feeds; yfinance. External: MedTech Dive (CGM and PFA market share), Mordor Intelligence (CGM market sizing), FTC 2022 infant-formula report. Full citation detail in the separate Source Appendix.

This article takes no recommendation and states no price target (the Author’s Take block excepted). Figures reconcile to primary filings; management commentary is treated as hypothesis and validated against filings, financials, and external data.

APPENDIX A — Standard Diligence Questionnaire

Abbott Laboratories (NYSE: ABT) — as of 2026-06-11

Supplemental to the memo. Grounded in the research notes; Fact/Interpretation/Assumption labeled where it matters.

General

What thoughtful questions have other investors asked about this company?

• Is the FreeStyle Libre franchise a structural GLP-1 victim or beneficiary? (The dominant debate.)
• What is the realistic aggregate exposure of the unreserved NEC infant-formula litigation?
• Is the ~$23bn Exact Sciences price (7.7× sales) disciplined or a reach, and when does it turn accretive?
• Is Abbott permanently behind in pulsed-field ablation (PFA), and does it matter?
• Is the Diagnostics margin (19.5%) a cyclical trough or a structural reset (China VBP)?
• Why does a double-digit-growing device franchise trade at a value-medtech multiple?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Mid-cycle, with two segments below trend. Medical Devices is at trend (strong); Diagnostics is at a cyclical low (COVID runoff + China VBP took margin from 24.4% to 19.5%); Nutrition is soft. So consolidated earnings are not at a cyclical peak — there is embedded recovery optionality in Diagnostics.

Driven by external environment or internal actions? Both. Internal: Libre penetration, structural-heart launches, margin/mix management. External: COVID-test demand (faded), China VBP, tariffs, FX, GLP-1 sentiment, litigation.

How stable are revenues? Fact: ~90%+ recurring/consumable (sensors, reagents, formula, chronic-care drugs). Diversification across four uncorrelated segments makes total revenue unusually stable for healthcare; the COVID spike/runoff is the main historical volatility.

Outlook for products/services? Fact/Interpretation: Devices (Libre, structural heart) double-digit; Diagnostics recovering + Exact growth; Nutrition low-single-digit (adult > pediatric); EPD mid-single-digit + biosimilars. Blended high-single-digit organic.

How big will this market be? CGM ~$10.5bn (2025) → ~$29bn (2030), <20% penetrated. IVD a large, mature oligopoly + cancer-dx adjacency (TAM doubled to >$120bn via Exact). Growing, global, ~61% international.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Interpretation: Stable-to-consolidating in devices/IVD (high barriers, EU MDR favors incumbents); PFA is an intensifying technology race where Abbott is behind; Nutrition faces private-label pressure.

How profitable is the business (ROIC, ROE)? Fact (normalized): ROIC ~12%, ROE ~13%, ROA ~7.8% (stripping the 2024 tax gain). Medical Devices ROIC is well above corporate average; Diagnostics/Nutrition dilutive; ~$24bn legacy goodwill (now $35bn post-Exact) drags consolidated ROIC.

How profitable is the industry — competitors, barriers? Devices/IVD are profitable oligopolies (20–31% peer op margins) with high barriers (clinical trials, FDA, physician relationships, reimbursement, agency pricing). Nutrition/EPD lower-barrier.

Can the business be easily understood? Interpretation: Moderately — four distinct segments require sub-sector knowledge, but each is a recognizable franchise. The accounting (2024 tax gain) is the main trap.

Undermined by foreign low-cost labor? No — regulated, IP- and reimbursement-protected products; manufacturing is quality/regulatory-gated, not labor-arbitraged.

Do brands matter? Yes in Nutrition (Similac, Ensure) and Libre (consumer-facing); less so in Core Lab (switching costs matter more than brand); EPD relies on aggregate brand trust + distribution.

Nature of competition / switching costs? Agency-priced devices (physician chooses); high switching costs in Core Lab (analyzer revalidation) and structural heart (physician training); habit/formulary stickiness in Libre. Low switching costs in Nutrition/EPD.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Interpretation: The Libre brand/installed base and structural-heart IP (organically built, so carried at ~zero intangible value) are worth far more than book — the core of the SOTP gap.

Off-balance-sheet liabilities? The unreserved NEC litigation is the material contingent liability (no accrual booked); standard operating leases and pension obligations otherwise.

How conservative is the accounting? Interpretation: Reasonably conservative on the operating side — adjusted EPS leaves SBC in the cost base (the honest kind). The one distortion is the 2024 tax-valuation-allowance release (non-cash, disclosed). No aggressive revenue or capitalization flags found.

How CapEx-hungry? Fact: Modest — capex ~$2.2bn/yr (~5% of revenue), stable; FCF conversion ~83% of adjusted NI. Not a capital-intensive business.

Capital Allocation & Management

How much FCF, and how is it used? Fact: ~$7.4bn FCF (2025). Priority order: dividend (~$4.1bn, ~55% of FCF) → M&A (Exact) → deleveraging → buybacks (residual, ~$0.6bn). Philosophy: dividend-anchored, organic-innovation-led, disciplined deleveraging.

Significant acquisitions recently? Fact: Exact Sciences ($105/sh, ~$23bn EV, closed Mar 2026) — the largest since St. Jude/Alere (2017). On-strategy adjacency at a full price.

Buying back shares? Modestly (~$0.6bn/yr); a $7bn authorization (Oct 2024) is largely unused, subordinated to deleveraging through 2027.

Issuing shares to insiders? SBC ~$0.66bn/yr (~1.5% of revenue), not excessive; not added back to adjusted EPS.

Compensation policy? Fact: CEO Ford $24.2m (2025); bonus on Adjusted Sales/EPS/ROA/FCF/Structural-Heart-growth; LTI on relative TSR + ROE gate. The 2025 sales miss correctly zeroed 25% of bonus. Say-on-pay ~91% (6-yr avg). Interpretation: per-share/return-aligned, not size-driven.

Motivations of management? Interpretation: Aligned — return/per-share metrics, modest but real insider ownership, two 2026 open-market insider buys.

Valuation & Market Data

ADR, MLP, or K-1? No — US-domestic C-corp, NYSE common, standard 1099 dividend.

Dividend policy? Dividend King (50+ yrs of increases); ~2.8% yield; ~55% FCF payout; ~7% recent growth.

How profitable? ~24% adjusted operating margin; ~57% gross margin; ~12% ROIC.

Net income diverging from cash flow? Fact: Only via the 2024 non-cash tax gain (reversed in OCF). Otherwise FCF tracks adjusted NI (~83% conversion) — clean.

Risks & Downside

What would cause the stock to decline? Libre growth deceleration (GLP-1), a large adverse NEC verdict/settlement, Diagnostics failing to recover, Exact disappointing, a guidance cut, tariff escalation.

Risk of catastrophic loss? Interpretation: Low. Diversified, profitable (~$7.4bn FCF), investment-grade (~2.2× net leverage), four uncorrelated legs. The realistic bear is a ~5–15% drawdown on a litigation/growth scare, not impairment.

Chance of total loss? Interpretation: Negligible — no plausible path for a diversified, cash-generative, investment-grade healthcare leader.

Recent News & Events

Has the business environment changed recently? Fact: Yes — Exact Sciences closed (Mar 2026); $20bn notes issued; NEC bellwether wins (2025); Volt PFA approved; tariffs introduced (~few hundred million). Net: deal-driven Diagnostics expansion + litigation de-risking against a GLP-1 sentiment overhang.

Significant acquisitions? Exact Sciences (covered above).

Change in accounting policies? None material beyond the disclosed 2024 tax-valuation-allowance release.

Recent changes — new markets, facilities, management? New GC and EVP Diabetes Care (2025); board expansion (Ahuja, Dec 2025); cancer-diagnostics market entry (Exact); Volt PFA, Tendyne, dual glucose-ketone sensor launches/filings.

APPENDIX B — Source Appendix

Abbott Laboratories (NYSE: ABT) — research sources, as of 2026-06-11

Sources are primary-first. All financial figures reconcile to SEC filings / EDGAR XBRL; management commentary is treated as hypothesis and validated against filings and external data.

Primary — SEC filings (EDGAR, CIK 0000001800)

Primary — transcripts (AZI feed; mirrored locally)

Primary — quantitative data feeds

Secondary — external

Key reconciliations / data notes

• FY2024 GAAP NI ($13.4B) is inflated by a $7.5B non-cash deferred-tax valuation-allowance release (10-K Note 15, −91.1% ETR) — normalized FY24 EPS ~$3.38. Any “−51% 2025 earnings decline” is an artifact.
• Net debt: ~$4.0B at FY25 year-end (pre-Exact); ~$26.8B post-deal (Q1-26 10-Q). yfinance EV (~$182B) reads post-deal — not an error, a timing difference.
• Revenue tag: modern RevenueFromContractWithCustomerExcludingAssessedTax (legacy Revenues returns nothing).
• Adjusted EPS does not add back SBC (the legitimate-amortization kind of non-GAAP).